Exosome based multivalent vaccine: achieving potent immunization, broadened reactivity, and strong T cell responses with nanograms of proteins
M. Cacciottolo, J. B. Nice, Y. Li, M. J. LeClaire, R. Twaddle, C. L. Mora, S. Y. Adachi, E. R. Chin, M. Young, J. Angeles, K. Elliott, M. Sun
This paper develops a multivalent exosome-based vaccine using nanogram doses of SARS-CoV-2 proteins without adjuvant, showing strong immune responses and cross-reactivity against variants.
bioRxiv · Jan 10, 2023 · PreprintImmunology